These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 26505567)

  • 1. Clinical characteristics and systemic therapies administered to first-time patients at a tertiary psoriasis outpatient clinic.
    Bonifati C; Graceffa D; Lora V; Maiani E
    G Ital Dermatol Venereol; 2016 Dec; 151(6):596-602. PubMed ID: 26505567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver fatty acid-binding protein might be a predictive marker of clinical response to systemic treatment in psoriasis.
    Baran A; Kiluk P; Maciaszek M; Świderska M; Flisiak I
    Arch Dermatol Res; 2019 Jul; 311(5):389-397. PubMed ID: 30993401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?
    Murdaca G; Spanò F; Contatore M; Guastalla A; Penza E; Magnani O; Puppo F
    Expert Opin Drug Saf; 2016 Jan; 15(1):43-52. PubMed ID: 26559805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Biologic and Conventional Systemic Therapies in Adults with Chronic Plaque Psoriasis in Daily Practice: A Systematic Review.
    Zweegers J; Otero ME; van den Reek JM; van Lümig PP; Driessen RJ; Kievit W; Seyger MM; van de Kerkhof PC; de Jong EM
    Acta Derm Venereol; 2016 May; 96(4):453-8. PubMed ID: 26537336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.
    Atzeni F; Costa L; Caso F; Scarpa R; Sarzi-Puttini P
    J Rheumatol Suppl; 2015 Nov; 93():79-81. PubMed ID: 26523064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing patients with psoriasis on injectable biologics adalimumab, etanercept, and ustekinumab: A chart review study.
    Zhang M; Goren A; Lee S; DiBonaventura MD; Olson WH
    J Dermatolog Treat; 2016 Aug; 27(4):339-45. PubMed ID: 26558924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis.
    Caso F; Lubrano E; Del Puente A; Caso P; Peluso R; Foglia F; Benigno C; Girolimetto N; Bottiglieri P; Scarpa R; Costa L
    Expert Rev Clin Immunol; 2016; 12(3):315-31. PubMed ID: 26558483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologics in inflammatory bowel disease: what are the data?
    Côté-Daigneault J; Bouin M; Lahaie R; Colombel JF; Poitras P
    United European Gastroenterol J; 2015 Oct; 3(5):419-28. PubMed ID: 26535119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
    Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
    Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of recalcitrant granuloma annulare (GA) with adalimumab: A single-center, observational study.
    Min MS; Lebwohl M
    J Am Acad Dermatol; 2016 Jan; 74(1):127-33. PubMed ID: 26552891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany.
    Iking-Konert C; von Hinüber U; Richter C; Schwenke H; Gürtler I; Kästner P; Klapperich B; Peters MA; Burmester GR
    Rheumatology (Oxford); 2016 Apr; 55(4):624-35. PubMed ID: 26515959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety profile of biologic therapy in Polish paediatric patients with Crohn's disease.
    Szymanska E; Dadalski M; Oracz G; Kierkus J
    Prz Gastroenterol; 2015; 10(3):164-8. PubMed ID: 26516383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B cell epitopes on infliximab identified by oligopeptide microarray with unprocessed patient sera.
    Homann A; Röckendorf N; Kromminga A; Frey A; Jappe U
    J Transl Med; 2015 Oct; 13():339. PubMed ID: 26511203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Non-bacterial chronic osteomyelitis: Experience in a tertiary hospital].
    Barral Mena E; Freire Gómez X; Enríquez Merayo E; Casado Picón R; Bello Gutierrez P; de Inocencio Arocena J
    An Pediatr (Barc); 2016 Jul; 85(1):18-25. PubMed ID: 26506888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short article: Remicade infusions at home: an alternative setting of infliximab therapy for patients with Crohn's disease.
    Kuin S; Stolte SB; van den Brink GR; Ponsioen CY; Fockens P; D'Haens GR; Löwenberg M
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):222-5. PubMed ID: 26566062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial.
    Kitko CL; Braun T; Couriel DR; Choi SW; Connelly J; Hoffmann S; Goldstein S; Magenau J; Pawarode A; Reddy P; Schuler C; Yanik GA; Ferrara JL; Levine JE
    Biol Blood Marrow Transplant; 2016 May; 22(5):862-8. PubMed ID: 26551636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic-free remission by orthopaedic surgery in non-responder to infliximab for rheumatoid arthritis.
    Kanbe K; Chiba J; Inoue Y; Taguchi M; Yabuki A
    Springerplus; 2015; 4():607. PubMed ID: 26543742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review on the efficacy and safety of Infliximab in patients with psoriasis.
    Wang J; Zhan Q; Zhang L
    Hum Vaccin Immunother; 2016; 12(2):431-7. PubMed ID: 26528924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does progranulin account for the opposite effects of etanercept and infliximab/adalimumab in osteoarthritis?: Comment on Olson et al.: "Therapeutic Opportunities to Prevent Post-Traumatic Arthritis: Lessons From the Natural History of Arthritis After Articular Fracture".
    Wei JL; Buza J; Liu CJ
    J Orthop Res; 2016 Jan; 34(1):12-4. PubMed ID: 26519939
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply to "Does progranulin account for the opposite effects of etanercept and infliximab/adalimumab in osteoarthritis?" by Wei et al.
    Olson SA; Furman BD; Kraus VB; Huebner JL; Guilak F
    J Orthop Res; 2016 Jan; 34(1):15-6. PubMed ID: 26519624
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.